Patricia Martín-Romano

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid et al. · Nature Cancer · 2022 · 120 citations · Full text

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Guillaume Manson, Alexandre Maria, F. Poizeau et al. · Journal for ImmunoTherapy of Cancer · 2019 · 102 citations · Full text

Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.

Alison M. Schram, Kōichi Goto, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2022 · 65 citations

Immunology, Pathology, Immunotherapy +17

The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study

Jean‐Marie Michot, Ariane Lappara, Jérôme Le Pavec et al. · European Journal of Cancer · 2020 · 59 citations

Clinical Immunology, Immunodeficiencies, Collaborative Management +11

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)

Andrea De Giglio, Laura Mezquita, Édouard Auclin et al. · Cancers · 2020 · 56 citations · Full text